In breast cancer, elevated expression of ENO1 has been reported to be closely related to tamoxifen resistance and adriamycin resistance (59), and silencing of ENO expression significantly increases the cytotoxicity of 100 nM tamoxifen in tamoxifen-resistant breast cancer cells. The gene discussed is ENO1; the disease is breast carcinoma.